Monthly Archives: August 2012

The Increasing Value of Medical Science Liaisons

By Ben Comer | Published: August 3, 2012

Can’t get your sales rep into that academic medical center? Try sending a medical science liaison (MSL). A new study from Industry Standard Research (ISR) found that MSLs enjoy better access and higher levels of trust among oncologists. Docs also want different kinds of information from MSLs, according to the study findings.

Posted in Advertising, Marketing, Medical Education, Sales, Strategy, patient education | Tagged ISR, Medical Science Liaison, MSL | 2 Comments

AIDS: ARV Optimism Tempered by Home Truths

By Jill Wechsler | Published: August 1, 2012

The prospect that antiretroviral drugs could prevent HIV infection in high-risk populations was the big news emerging from last month’s International AIDS Conference in Washington, DC. But the news raises the tricky ethical question of whether the US should spend $11,000 per patient to keep uninfected individuals healthy, when funds are lacking to provide life-saving treatment [...]

Posted in FDA, Guest Blog, healthcare | Tagged AIDS, antiretroviral, antiviral, ARVs, Centers for Disease Control and Prevention, FDA, National Institute of Allergy and Infectious Diseases, National Institutes of Health | Leave a comment

Three Questions to Ask About Your Life Sciences Patents

By Guest Blogger | Published: August 1, 2012

By Marian T. Flattery and Michael J. Flibbert The decisions you make today about patents – what, when and where to file – could have implications tantamount to billions of dollars in R&D investment and sales over the next two decades. Given the increasing importance of lifecycle management in the context of increasing generic usage [...]

Posted in IP, Legal, R&D | Tagged America Invents Act, patents, US Patent and Trademark Office | Leave a comment

Challenges in the March Toward an AIDS-Free Generation

By Ben Comer | Published: August 1, 2012

FDA’s approval of Truvada, a once-a-day oral combination of tenofovir and emtricitabine, for pre-exposure prophylaxis (or PrEP, a method for preventing HIV infection) arrived during a chorus of optimism surrounding major developments in the fight against AIDS.

Posted in Biotech, Events, FDA, Market Access, Patient Communication, Regulatory, Safety, healthcare, patient compliance, patient education, pricing | Tagged AIDS, Antiretroviral drug, Bill & Melinda Gates Foundation, conference, Gilead Sciences, HIV, HIV/AIDS, NIAID | Leave a comment